EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Neurolipid systems: A new target for the treatment of dementia

Gorka Pereira-Castelo, Iker Bengoetxea de Tena iD, Jonatan Martínez-Gardeazabal, Marta Moreno-Rodríguez, Estibaliz González de San Román, Iván Manuel iD, Rafael Rodríguez-Puertas

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.14059 ↗

At a glance

Übersichtsarbeit in Basic & Clinical Pharmacology & Toxicology, 2024. Written by Gorka Pereira-Castelo and 6 co-authors. Institution: Department of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Spain. Major MEDLINE topics: Dementia, Lysophospholipids. Cited 6 times so far (Crossref); 82 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Basque Government, Instituto de Salud Carlos III, Eitb Maratoia.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Neurolipids comprise a diverse class of bioactive lipids that include molecules capable of activating G protein‐coupled receptors, thereby inducing systemic effects that contribute to the maintenance of homeostasis. Dementia, a non‐specific brain disorder characterized by a common set of signs and symptoms, usually arises subsequent to brain injuries or diseases and is often associated with the aging process. Individuals affected by dementia suffer from the disruption of several neurotransmitter and neuromodulatory systems, among which neurolipids play an important role, including the endocannabinoid, lysophosphatidic acid and sphingosine 1‐phosphate systems. In this review, we present an overview of the most recent and pertinent findings regarding the involvement of these neurolipidic systems in dementia, including data from a wide range of both in vitro and in vivo experiments as well as clinical trials.

Subjects

MeSH terms (MEDLINE)

DementiaLysophospholipidsHumansAnimalsSphingosineEndocannabinoidsReceptors, G-Protein-CoupledBrainNeurotransmitter Agents

Author keywords

dementiaendocannabinoidlysophosphatidic acidneurolipidsphingosine 1‐phosphate

Substances

Lysophospholipidslysophosphatidic acidSphingosinesphingosine 1-phosphateEndocannabinoidsReceptors, G-Protein-CoupledNeurotransmitter Agents

Authors and institutions

  • Department of Pharmacology, University of the Basque Country (UPV/EHU), Leioa, Spain.
  • Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, Arizona, USA.
  • Neurodegenerative Diseases, BioBizkaia Health Research Institute, Barakaldo, Spain.

ORCID profiles: Iker Bengoetxea de Tena, Iván Manuel

Funding

  • Basque Government
  • Instituto de Salud Carlos III
  • Eitb Maratoia
  • Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza

Cite

APA

Pereira-Castelo, G., Bengoetxea de Tena, I., Martínez-Gardeazabal, J., Moreno-Rodríguez, M., de San Román, E. G., Manuel, I., & Rodríguez-Puertas, R. (2024). Neurolipid systems: A new target for the treatment of dementia. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14059

Vancouver

Pereira-Castelo G, Bengoetxea de Tena I, Martínez-Gardeazabal J, Moreno-Rodríguez M, de San Román EG, Manuel I, et al. Neurolipid systems: A new target for the treatment of dementia. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14059

BibTeX
@article{PereiraCastelo2024,
  author = {Pereira-Castelo, Gorka and Bengoetxea de Tena, Iker and Martínez-Gardeazabal, Jonatan and Moreno-Rodríguez, Marta and de San Román, Estibaliz González and Manuel, Iván and Rodríguez-Puertas, Rafael},
  title = {Neurolipid systems: A new target for the treatment of dementia},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.14059}
}
Start for free →